SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating ...
The last time I wrote an article on Alector, Inc. (ALEC), I analyzed its enormous potential in using its TREM2 receptor drug AL002 being studied in the phase 2 INVOKE-2 trial, which was targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results